TP53 and Familial prostate cancer: Our study leads us to conclude that pre-existing TP53 mutations (i.e., loss of function) in hormone- dependent prostate cancer cells can contribute to the development of CRPC, likely via both facilitating the proliferation of and promoting the genomic instability in tumor cells.